Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

Yesterday

Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.

The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1194401477"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194401477\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194401477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194401477","market":"hk","top_or_hot":-1,"title":"Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.</p>\n<p>The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-06 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.</p>\n<p>The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1194401477","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194401477","pubTimestamp":1770391303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"北京映泰药业(2563)收到证监会H股全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.\nThe company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}